Acadia Pharmaceuticals
12830 El Camino Real, Suite 400
San Diego
California
92130
United States
Tel: (858) 558-2871
Website: https://www.acadia-pharm.com/
571 articles about Acadia Pharmaceuticals
-
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results
5/4/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2022.
-
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences - May 03, 2022
5/3/2022
Acadia Pharmaceuticals Inc. announced that it will participate at the following upcoming investor conferences.
-
Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022
5/2/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that a virtual meeting of the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee to review the resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) has been scheduled for June 17, 2022.
-
Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022
4/21/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after the close of the U.S. financial markets.
-
Acadia Pharmaceuticals faces a major hurdle after top-line results from its study of ACP-044 for post-surgery pain failed to meet desired outcomes.
-
Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain
4/18/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery.
-
The company presented an update on its Phase III LAVENDER study of trofinetide for Rett syndrome at the American Academy of Neurology's annual meeting in Seattle.
-
Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN)
3/22/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced a late-breaking oral presentation on the efficacy and safety data from the Phase 3 Lavender study of trofinetide, an investigational treatment for Rett syndrome (RTT), will be presented at the 2022 American Academy of Neurology Annual Meeting (AAN), held in Seattle, WA, April 2-7, and virtually April 24-26, 2022.
-
Acadia Pharmaceuticals to Present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022
3/10/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 1st Annual Needham Virtual Neuroscience Forum on Wednesday, March 16, 2022 at 3:20 p.m. Eastern Time.
-
This target date is the latest development in a long series of setbacks that Acadia - and other pharma companies - have experienced getting Alzheimer’s treatments approved.
-
Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
3/9/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has received a target action date of August 4, 2022 from the U.S. Food and Drug Administration (FDA) for its resubmitted supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).
-
Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
3/3/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 2:50 p.m. Eastern Time.
-
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
2/28/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2021.
-
In April 2021, the U.S. Food and Drug Administration issued Acadia a Complete Response Letter (CRL) related to its previous attempt to expand the approved indication for Nuplazid.
-
Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimer’s Disease Psychosis
2/16/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it has resubmitted its supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) to the U.S. Food and Drug Administration (FDA).
-
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
2/14/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022, after the close of the U.S. financial markets.
-
Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022
2/11/2022
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 1:40 p.m. Eastern Time.
-
Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
1/10/2022
Acadia Pharmaceuticals and Stoke Therapeutics, Inc. announced today that the companies have entered a collaboration to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS).
-
The collaboration covers several neurodevelopmental targets, including Rett syndrome, SYNGAP1 syndrome, and one other disease yet to be disclosed.
-
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
12/22/2021
Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022.